AlloVir Inc. (ALVR) Stock Price, Quote & News

AI Score

Unlock

AI Score

Our AI model analyzes fundamental, technical, and statistical indicators to predict the probability of a bullish trend over the next three months.

We regularly update and refine our models to deliver the most reliable forecasts for you.

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

AlloVir Inc. (ALVR)

AI Score

Unlock

AI Score

Bullish Probability	Sentiment	Score
+80%	Strong Buy	10
+75%	Buy	9
+70%	Buy	8
+60%	Buy	7
+50%	Hold	6
+45%	Hold	5
+40%	Hold	4
+35%	Sell	3
+30%	Sell	2
+20%	Strong Sell	1

0.41

0.01 (2.50%)

At close: Jan 15, 2025, 1:54 PM

undefined% (undefined)

Bid	0.4
Market Cap	47.37M
Revenue (ttm)	-
Net Income (ttm)	-
EPS (ttm)	-0.88
PE Ratio (ttm)	-0.47
Forward PE	n/a
Analyst	Sell

Ask	0.42
Volume	788,574
Avg. Volume (20D)	410,620
Open	0.45
Previous Close	0.40
Day's Range	0.39 - 0.45
52-Week Range	0.38 - 1.05
Beta	undefined

About ALVR

Allovir, Inc., a clinical-stage cell therapy company, engages in the research and development of allogeneic, off-the-shelf multi-virus specific T cell (VST) therapies to prevent and treat devastating viral-associated diseases. The company's lead product is posoleucel, an allogeneic, off-the-shelf VST therapy, to treat BK virus, cytomegalovirus, adenovirus, Epstein-Barr virus, human herpesvirus 6, and JC virus. Its preclinical and clinical develop...

[Show more]

Industry Biotechnology

Sector Healthcare

IPO Date Jul 30, 2020

Employees 8

Stock Exchange NASDAQ

Ticker Symbol ALVR

Website https://www.allovir.com

Analyst Forecast

According to 1 analyst ratings, the average rating for ALVR stock is "Sell." The 12-month stock price forecast is $0.5, which is an increase of 21.98% from the latest price.

Buy 0.00%

Hold 0.00%

Sell 100.00%

Stock Forecasts

Why Price Moved

2 months ago · Source

-36.93%

AlloVir shares are trading lower. The company anno... Unlock content with Pro Subscription

News

2 months ago · businesswire.com

ALLOVIR INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of AlloVir, Inc. - ALVR

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed merger of AlloVir, Inc. ...

2 months ago · businesswire.com

Shareholder Alert: Ademi LLP Investigates Whether AlloVir, Inc. Is Obtaining a Fair Price for Its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating AlloVir (Nasdaq: ALVR) for possible breaches of fiduciary duty and other violations of law in its transaction with Kalaris. Click here to learn h...

2 months ago · businesswire.com

ALVR Stock Alert: Halper Sadeh LLC is Investigating Whether the Merger of AlloVir, Inc. Is Fair to Shareholders

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the merger of AlloVir, Inc. (NASDAQ: ALVR) and Kalaris Therapeutics is fair to AlloVir shareholders. ...